A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer.
Cancer Invest
; 35(8): 535-540, 2017 Sep 14.
Article
em En
| MEDLINE
| ID: mdl-28792245
ABSTRACT
BACKGROUND:
This phase II study combined aflibercept with preoperative chemoradiation for patients with stage II/III rectal cancer, followed by mFOLFOX6/aflibercept.METHODS:
Patients received preoperative 5-FU (days 1-43), radiation (weeks 1-6), and aflibercept (days 1-15) each 28 day cycle for 6 weeks. Six weeks following the last aflibercept dose, patients underwent surgical resection. Four cycles of mFOLFOX6 plus aflibercept began 8 weeks after surgery.RESULTS:
Common treatment-related toxicities included diarrhea, fatigue, and mucositis. The pCR rate was 23%.DISCUSSION:
Afilbercept plus 5-FU-based chemoradiation was tolerated in patients with localized rectal cancer and showed a pCR rate within range of historical data.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Retais
/
Proteínas Recombinantes de Fusão
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Terapia Combinada
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Fluoruracila
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Invest
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Estados Unidos